Abiopharma

🔍 RA CAPITAL MANAGEMENT, L.P. (Executive)

Company: Acrivon Therapeutics, Inc. (ACRV)

Report Date: 2026-06-17

Detailed Transactions and Holdings:

• Acquired 20,275 shares of Stock Option (Right to Buy) at $1.52 per share (Derivative)
  Date: 2026-06-17 | Code: A | Expires: 2036-06-16 | equity_swap_involved: 0 | shares_owned_after: 20,275.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to Dr. Derek DiRocco's continuous service through the applicable vesting date.
• F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
• F3: Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the option for the benefit of the Fund and the Nexus Fund II. Dr. DiRocco is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
• REMARKS: Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.